Supernus Pharmaceuticals Inc (SUPN)

Return on total capital

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 4,194 38,528 29,919 59,270 65,413 35,337 68,942 92,510 92,871 130,083 153,997 170,320 188,083 188,802 175,255 170,365 165,694 166,697 162,190 152,235
Long-term debt US$ in thousands — — — — — 0 0 400,382 379,252 374,788 370,383 366,038 361,751 357,521 353,349 349,232 345,170 341,163 337,210 333,310
Total stockholders’ equity US$ in thousands 1 912,191 919,908 912,150 0 852,798 841,434 828,446 815,851 810,468 785,579 754,444 744,858 708,879 665,974 613,383 595,428 557,257 522,904 480,018
Return on total capital 419,400.00% 4.22% 3.25% 6.50% — 4.14% 8.19% 7.53% 7.77% 10.98% 13.32% 15.20% 17.00% 17.70% 17.19% 17.70% 17.62% 18.55% 18.86% 18.72%

December 31, 2023 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $4,194K ÷ ($—K + $1K)
= 419,400.00%

To analyze Supernus Pharmaceuticals Inc's return on total capital, we observe fluctuations in the ratio over the past eight quarters. The return on total capital ranged between 1.45% and 5.53% during this period. Notably, the ratio peaked at 5.53% in Q1 2022, subsequently experiencing a decline in Q2 and Q3 2022 before a slight recovery in Q4 2022.

In the latest quarter, Q4 2023, Supernus Pharmaceuticals Inc's return on total capital stood at 1.45%, showing a decrease compared to the previous quarter, Q3 2023, where it was 2.89%. This decline indicates potential challenges in utilizing the company's total capital efficiently to generate returns for shareholders.

Overall, fluctuations in return on total capital can reflect changes in the company's operational efficiency, profitability, and capital structure. It is essential for stakeholders to monitor this ratio closely to assess Supernus Pharmaceuticals Inc's performance and financial health over time.